Track GKOS's AI-powered predictions, market trends, and investment insights.
You don't hold GKOS in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedGlaukos is currently unprofitable, as indicated by its negative EPS and PE ratio, implying that investors are paying for future growth rather than current earnings. The lack of positive net income and profitability pressures suggest fundamental risk, even if revenue may be growing in the background. Until the company demonstrates a clear path to sustainable profitability, fundamentals lean negative.
The stock’s recent 14.7% gain over the last month and its trading level well above the 200-day moving average signal strong positive momentum. Being significantly above the 200-day MA often reflects a sustained uptrend and constructive market sentiment. While RSI was not provided, the magnitude of the recent move suggests the stock may be approaching overbought territory, but the prevailing trend remains upward.
Alternative data for Glaukos shows constructive growth signals, particularly in hiring and professional engagement. Job openings are up over 20% month over month, suggesting expansion and investment in future operations. Social media presence, especially on LinkedIn, is steadily growing, pointing to rising professional interest and brand visibility, even as consumer-facing channels grow more modestly.
Glaukos exhibits strong stock price momentum and positive alternative data signals, but these are set against a backdrop of ongoing unprofitability. The market appears to be pricing in significant future growth and operational progress, while fundamentals have yet to fully catch up. Taken together, the picture is balanced: sentiment and trend are supportive, but financial risk remains elevated.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos Announces the Release of its 2025 Sustainability Report
Glaukos Corporation (GKOS) is trading at $143.82 on the NYSE, posting a notable single-session gain of +2.8% on volume of 811,340 shares. With a market capitalization of $8.4 billion, Glaukos occupies a meaningful position within the ophthalmic medical technology sector. The company's commercial portfolio — anchored by its iStent micro-bypass stent family used in cataract surgery for mild-to-moderate open-angle glaucoma — continues to underpin its revenue base. The day's price momentum reflects renewed investor attention, though whether this represents a sustained directional move or a short-term spike warrants careful examination of underlying fundamentals and forward catalysts.
TrendEdge's AI model assigns Glaukos a score of 6 out of 10 — a neutral-to-modestly-positive reading that suggests the stock carries genuine opportunity but lacks the broad signal convergence needed to rate as a strong conviction buy. The score reflects a company in active growth mode: 37 open job postings indicate operational expansion, particularly relevant for a business scaling pipeline products like iStent Infinite and the iDose TR targeted injectable implant. However, the absence of web traffic trend data and app download metrics limits the AI's ability to triangulate demand-side momentum, keeping the score from moving higher without stronger corroborating signals.
Key catalysts to monitor for GKOS in 2026 include regulatory and commercial progress on iDose TR, its sustained-release drug delivery implant targeting glaucoma, and the standalone refractory glaucoma positioning of iStent Infinite. With 37 active job postings suggesting pipeline and commercial investment, execution risk is real. Investors should watch for clinical data updates, reimbursement developments, and competitive pressure in the ophthalmic device space. The $8.4B market cap prices in meaningful growth expectations, meaning any pipeline delays or adoption shortfalls could weigh disproportionately on valuation.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
27,688
Twitter Followers
1,632
Instagram Followers
4,301
LinkedIn Followers
36,890
Job Postings
40
LinkedIn Employees
1,075
News Mentions
0
Key Metrics
